| 2026年中报 | 2025年年报 | 2025年中报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 多肽类产品(元) | 33,213,163.12 | 84,946,163.97 | 40,072,884.96 | 82,605,702.00 | 41,722,494.51 |
| 受托业务(元) | 15,027,503.87 | - | 11,696,639.40 | - | 19,839,370.75 |
| 受托研发业务(元) | - | 24,042,798.93 | - | 40,289,445.68 | - |
| 复杂制剂(元) | 61,535,565.36 | 141,097,090.07 | - | - | - |
| 其他产品(元) | 4,960,867.63 | 21,263,744.67 | 28,840,484.04 | 46,599,545.61 | 31,013,567.48 |
| 营业成本(元) | |||||
| 多肽类产品(元) | 18,166,551.88 | 56,162,923.24 | 21,439,150.46 | 35,456,374.22 | 16,535,690.30 |
| 受托业务(元) | 9,736,365.29 | - | 6,415,866.01 | - | 8,260,950.34 |
| 受托研发业务(元) | - | 8,976,587.13 | - | 20,098,345.52 | - |
| 复杂制剂(元) | 9,444,328.98 | 47,216,073.05 | - | - | - |
| 其他产品(元) | 1,858,611.85 | 11,869,074.27 | 16,468,763.22 | 19,257,648.26 | 10,960,649.06 |
| 毛利(元) | |||||
| 多肽类产品(元) | 15,046,611.24 | 28,783,240.73 | 18,633,734.50 | 47,149,327.78 | 25,186,804.21 |
| 受托业务(元) | 5,291,138.58 | - | 5,280,773.39 | - | 11,578,420.41 |
| 受托研发业务(元) | - | 15,066,211.80 | - | 20,191,100.16 | - |
| 复杂制剂(元) | 52,091,236.38 | 93,881,017.02 | - | - | - |
| 其他产品(元) | 3,102,255.78 | 9,394,670.40 | 12,371,720.82 | 27,341,897.35 | 20,052,918.42 |
| 毛利率(%) | |||||
| 多肽类产品(%) | 45.30 | 33.88 | 46.50 | 57.08 | 60.37 |
| 受托业务(%) | 35.21 | - | 45.15 | - | 58.36 |
| 受托研发业务(%) | - | 62.66 | - | 50.12 | - |
| 复杂制剂(%) | 84.65 | 66.54 | - | - | - |
| 其他产品(%) | 62.53 | 44.18 | 42.90 | 58.67 | 64.66 |
| 收入构成(%) | |||||
| 多肽类产品(%) | 28.95 | 31.31 | 49.71 | 48.74 | 45.07 |
| 受托业务(%) | 13.10 | - | 14.51 | - | 21.43 |
| 受托研发业务(%) | - | 8.86 | - | 23.77 | - |
| 复杂制剂(%) | 53.63 | 52.00 | - | - | - |
| 其他产品(%) | 4.32 | 7.84 | 35.78 | 27.49 | 33.50 |
| 毛利构成(%) | |||||
| 多肽类产品(%) | 19.92 | 19.56 | 51.35 | 49.80 | 44.33 |
| 受托业务(%) | 7.01 | - | 14.55 | - | 20.38 |
| 受托研发业务(%) | - | 10.24 | - | 21.33 | - |
| 复杂制剂(%) | 68.97 | 63.81 | - | - | - |
| 其他产品(%) | 4.11 | 6.39 | 34.09 | 28.88 | 35.29 |